Search

Calcium phosphate dihydrate

Cholecystokinin

Recent studies have suggested that cholecystokinin also plays a major role in inducing drug tolerance to opioids such as morphine and heroin, and is partially implicated in experiences of pain hypersensitivity … Soon after, it was recognized to be identical to the factor responsible for stimulating pancreatic exocrine secretion in 1943 [L1636].

Estradiol cypionate

These include hot flashes, vaginal dryness, mood changes, irregular menses, chills, and sleeping problems. … , estrone and estriol at the receptor level.

Estradiol acetate

These include hot flashes, vaginal dryness, mood changes, irregular menses, chills, and sleeping problems. … , estrone and estriol at the receptor level.

Calcium Phosphate

Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] [L851].

Quinacrine

An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. … It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.

Pemigatinib

With increasing research on the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drug treatment, recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma … [L13068] Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy.

Daptomycin

tryptophan covalently bonded to decanoic acid. … [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]

MF101

MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women. … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation

Anecortave

Anecortave is under investigation in clinical trial NCT00691717 (Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension).